JP6963545B2 - 癌を治療するための併用療法 - Google Patents

癌を治療するための併用療法 Download PDF

Info

Publication number
JP6963545B2
JP6963545B2 JP2018517826A JP2018517826A JP6963545B2 JP 6963545 B2 JP6963545 B2 JP 6963545B2 JP 2018517826 A JP2018517826 A JP 2018517826A JP 2018517826 A JP2018517826 A JP 2018517826A JP 6963545 B2 JP6963545 B2 JP 6963545B2
Authority
JP
Japan
Prior art keywords
cancer
agents
tumor
compound
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018517826A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018533560A5 (enExample
JP2018533560A (ja
Inventor
レザ・ファシ
ドゥロール・ベン−アッシャー
ダニエル・エイブラムソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Redhill Biopharma Ltd
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Publication of JP2018533560A publication Critical patent/JP2018533560A/ja
Publication of JP2018533560A5 publication Critical patent/JP2018533560A5/ja
Application granted granted Critical
Publication of JP6963545B2 publication Critical patent/JP6963545B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018517826A 2015-10-06 2016-10-06 癌を治療するための併用療法 Active JP6963545B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562237925P 2015-10-06 2015-10-06
US62/237,925 2015-10-06
PCT/IB2016/001526 WO2017060771A2 (en) 2015-10-06 2016-10-06 Combination therapies for treating cancer

Publications (3)

Publication Number Publication Date
JP2018533560A JP2018533560A (ja) 2018-11-15
JP2018533560A5 JP2018533560A5 (enExample) 2019-11-14
JP6963545B2 true JP6963545B2 (ja) 2021-11-10

Family

ID=58446480

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018517826A Active JP6963545B2 (ja) 2015-10-06 2016-10-06 癌を治療するための併用療法

Country Status (12)

Country Link
US (4) US9844540B2 (enExample)
EP (1) EP3359255A4 (enExample)
JP (1) JP6963545B2 (enExample)
KR (1) KR20180058716A (enExample)
CN (1) CN108136207A (enExample)
AU (1) AU2016336133B2 (enExample)
BR (1) BR112018003232A2 (enExample)
CA (1) CA2997671A1 (enExample)
HK (1) HK1259342A1 (enExample)
MX (1) MX382754B (enExample)
RU (1) RU2727474C2 (enExample)
WO (1) WO2017060771A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4134076A1 (en) 2014-10-24 2023-02-15 Redhill Biopharma Ltd. Therapy for inhibition of single-stranded rna virus replication
WO2018195434A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
CA3060509A1 (en) 2017-04-21 2018-10-25 Federica Sotgia Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
KR20200010343A (ko) 2017-05-19 2020-01-30 루넬라 바이오테크 인코포레이티드 안티미토신: 암 줄기 세포를 근절하기 위한 미토콘드리아 생물발생의 표적화 억제제
WO2018213764A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
EP3644988B1 (en) 2017-06-26 2023-02-22 Lunella Biotech, Inc. Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells
JP2020534285A (ja) 2017-09-15 2020-11-26 アンパサンド バイオファーマシューティカルズ インコーポレイテッドＡｍｐｅｒｓａｎｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 投与および処置の方法
EP3681494A4 (en) * 2017-09-15 2021-08-04 Ampersand Biopharmaceuticals, Inc. INHIBITION OF SPONTANEOUS METASTASIS BY PROTEIN INHIBITORS OF CYSTEIN PROTEASES
BR112021013952A2 (pt) * 2019-01-16 2021-11-16 Apogee Biotechnology Corp Métodos de indução de uma resposta imunológica anticâncer
WO2020154716A1 (en) * 2019-01-26 2020-07-30 University Of Rochester Compositions and methods for treating prostate cancer
CA3174438A1 (en) * 2020-03-10 2021-09-16 Redhill Biopharma Ltd. Treatment of coronavirus infection
US11471448B2 (en) 2020-12-15 2022-10-18 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
CN119700770A (zh) * 2025-01-09 2025-03-28 首都医科大学附属北京佑安医院 氯法齐明在制备修复肠黏膜或改善肠道菌群药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2189001A1 (en) * 1994-04-26 1995-11-02 Nobuhiro Narita Medicinal composition as a remedy for nonsmall cell lung cancer
AUPP437698A0 (en) * 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
DE59909210D1 (de) * 1998-07-20 2004-05-19 Wilex Ag Urokinase-Inhibitoren
AUPR644301A0 (en) * 2001-07-17 2001-08-09 Unisearch Limited Method and composition for treatment of cancer
US6864264B1 (en) * 2002-08-20 2005-03-08 Gloria L. Anderson 1-adamantyl chalcones for the treatment of proliferative disorders
DE10323898A1 (de) * 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
DE102004057195A1 (de) * 2004-11-26 2006-06-01 Wilex Ag Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon
US20060142304A1 (en) * 2004-12-27 2006-06-29 Michael Southall Method for treating or preventing pruritic and neurogenic skin disorders
US20060270631A1 (en) * 2005-05-26 2006-11-30 Smith Charles D Methods for the treatment and prevention of angiogenic diseases
ES2528451T3 (es) * 2005-06-17 2015-02-10 Apogee Biothechnology Corporation Inhibidores de esfingosina cinasa
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
US20080226624A1 (en) * 2007-03-07 2008-09-18 Wolfgang Schmalix Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect
HRP20190045T1 (hr) * 2008-02-08 2019-03-08 Red Hill Biopharma Ltd. Metode i sastavi za liječenje upalne bolesti crijeva
TWI573590B (zh) * 2011-09-20 2017-03-11 雷希爾生藥有限公司 治療自體免疫疾病之組成物及方法
EP3560497A1 (en) * 2012-08-30 2019-10-30 The Texas A&M University System Compositions and methods for drug-sensitization or inhibition of a cancer cell
EP4134076A1 (en) * 2014-10-24 2023-02-15 Redhill Biopharma Ltd. Therapy for inhibition of single-stranded rna virus replication

Also Published As

Publication number Publication date
US20170095460A1 (en) 2017-04-06
CN108136207A (zh) 2018-06-08
MX382754B (es) 2025-03-13
US11633385B2 (en) 2023-04-25
WO2017060771A3 (en) 2017-07-06
RU2018109902A3 (enExample) 2020-03-05
KR20180058716A (ko) 2018-06-01
US20210128538A1 (en) 2021-05-06
HK1259342A1 (zh) 2019-11-29
MX2018004309A (es) 2018-05-22
US10463654B2 (en) 2019-11-05
EP3359255A2 (en) 2018-08-15
AU2016336133A1 (en) 2018-03-15
BR112018003232A2 (pt) 2018-09-25
AU2016336133B2 (en) 2021-02-25
US10946000B2 (en) 2021-03-16
CA2997671A1 (en) 2017-04-13
WO2017060771A2 (en) 2017-04-13
JP2018533560A (ja) 2018-11-15
US20200113881A1 (en) 2020-04-16
RU2727474C2 (ru) 2020-07-21
RU2018109902A (ru) 2019-11-07
EP3359255A4 (en) 2019-06-12
US9844540B2 (en) 2017-12-19
US20180125831A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
JP6963545B2 (ja) 癌を治療するための併用療法
JP7014731B2 (ja) 置換アミノプリン化合物、その組成物、及びそれらを用いた治療方法
RU2757373C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
EP2034835B1 (en) Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
KR20140025374A (ko) 3-(5-아미노-2-메틸-4-옥소-4ｈ-퀴나졸린-3-일)-피페리딘-2,6-디온을 사용하는 암의 치료 방법
US20140051662A1 (en) Treatment of multiple myeloma with masitinib
KR20160078987A (ko) 플리나불린 및 탁산의 조합에 의한 암 치료
WO2014007998A1 (en) SORAFENIB DERIVATIVES AS p21 INHIBITORS
WO2021048417A1 (en) Combination therapies comprising dasatinib for the treatment of cholangiocarcinoma
KR20060124610A (ko) 석면-관련된 질환 또는 장애를 치료 및 관리하기 위하여ｊｎｋ 억제제를 사용하는 방법 및 이 물질을 포함하는조성물
JP2015505313A (ja) 癌を治療するための併用療法
US20220409582A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
WO2021048419A1 (en) Combination therapies comprising trametinib for the treatment of cholangiocarcinoma
BR112020009596A2 (pt) combinações de moduladores duplos de irs/stat3 e anticorpos anti pd-1/pd-l1 para tratar câncer
TWI827310B (zh) 異硫氰酸酯結構修飾化合物於預防或治療肝臟疾病之用途
US12472227B2 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
US20250120970A1 (en) Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug
WO2021048418A1 (en) Combination therapies comprising bortezomib for the treatment of cholangiocarcinoma
CN102781444A (zh) 用于治疗肝细胞癌的抗肿瘤剂或手术后辅助化学治疗剂
CN118555959A (zh) 心脏保护方法
HK1229695A1 (en) Novel methods for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191004

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210708

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210708

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210824

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210902

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210907

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211005

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211015

R150 Certificate of patent or registration of utility model

Ref document number: 6963545

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250